Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Palliative Radiation for Advanced Cervical Cancer (RAPPAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03997110
Recruitment Status : Not yet recruiting
First Posted : June 25, 2019
Last Update Posted : March 20, 2020
Sponsor:
Collaborator:
Tata Memorial Centre
Information provided by (Responsible Party):
Supriya Sastri (chopra), Tata Memorial Hospital

Brief Summary:
The present study is proposed to compare a rapid fractionation schedule of 1 week compared to a protracted schedule of 6-8 weeks for palliation for locally advanced cervical cancer.

Condition or disease Intervention/treatment Phase
Cervical Cancer Radiation: Short course palliative radiation. Radiation: Long course palliative treatment. Phase 3

Detailed Description:

This is a prospective randomised open label Phase III study. This study is is proposed to compare a rapid fractionation schedule of 1 week compared to a protracted schedule of 6-8 weeks for palliation for locally advanced cervical cancer. The primary objective of the study is pain relief in the experimental arm as compared to the control arm from treatment until 12 weeks from start of radiotherapy. Patients with locally advanced cervical cancer (Stage III B-IV A) deemed unsuitable for full course radical pelvic radiotherapy or chemoradiation, patients whose anticipated survival is less than 12 months will be included in the study. Patients with distant metastasis and those with retroviral disease will be excluded from the study. The patients will be randomised in one of the two groups:

Arm A : Control Arm - Long Course Palliative Radiation: Week 1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week 4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week 7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients which will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity.

Arm B: Experimental arm- Short Course Palliative radiation. Week 1: Patients will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.There is no potential direct benefit to the study participants. However the aim is to use the available information to evolve treatment in future. The variables to be estimated are pain relief, disease related symptoms relief, CTCAE Toxicity, Quality of Life,overall survival and compliance to therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 230 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase III, Randomized, Active Controlled Trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rapid Palliation in Locally Advanced Cervical Cancer: A Phase III Randomized Trial
Estimated Study Start Date : May 1, 2020
Estimated Primary Completion Date : August 1, 2024
Estimated Study Completion Date : February 1, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Arm A Or Control Arm- Long course palliative treatment.
Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
Radiation: Long course palliative treatment.
Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity

Experimental: Arm B or Experimental Arm-Short course palliative radiation.
Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
Radiation: Short course palliative radiation.
Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.




Primary Outcome Measures :
  1. Pain Relief (Numerical pain rating scale will be used) [ Time Frame: 1 week, 4 week, 7 week, 12 weeks ]

    Pain relief in the experimental arm as compared to the control arm from treatment until 12 weeks from start of radiotherapy will be assessed.

    Pain relief will be assessed at 12 weeks from start of radiotherapy. (Pain has been chosen as the primary endpoint as it is the primary complaint in almost 2/3 rd of patients. Numerical pain rating scale has been chosen for objective pain assessment as it is easy to use and has been proven to be a reliable tool in multiple studies.

    Pain score will be documented on 11-scale numerical pain rating scale (NRS) and qualified into one of the following categories:

    i)Pain score of 0-3- No to mild pain ii)Pain score 4-7- Moderate pain iii)Pain score >7- Severe pain



Secondary Outcome Measures :
  1. Pain Relief (Numerical pain rating scale will be used) [ Time Frame: 6 months, 9 months, 12 months ]

    Pain relief at 6, 9 and 12 month of follow up.

    Pain score will be documented on 11-scale numerical pain rating scale (NRS) and qualified into one of the following categories:

    i) Pain score of 0-3- No to mild pain ii) Pain score 4-7- Moderate pain iii) Pain score >7- Severe pain


  2. Presence or absence of vaginal bleeding and/or discharge and relief in vaginal bleeding (as reported by the patient) [ Time Frame: 1 week,4 week,7week,12 weeks ]

    Complete relief in vaginal bleeding and non-infectious discharge will be documented at 12 weeks from start of RT as reported by the patient. Although vaginal bleeding and discharge are also major presenting complaints, there is no standardized objective scale or criteria for measuring these in cancer patients.

    Vaginal discharge if present will be qualified as infectious or non-infectious. Infectious vaginal discharge will warrant antibiotic treatment.


  3. Change in use of analgesics (WHO ladder) [ Time Frame: 12 weeks, 3 month, 9 month, 12 month ]
    Change in use of analgesics by either dose adjustment or stepping up/down on the WHO ladder at 12 weeks.This will also be recorded at each clinical follow up.

  4. Compliance to therapy [ Time Frame: 7 week,12 week, 3 month, 9 month, 12 month ]
    Response of local disease will be assessed clinically at end of treatment and on every follow up. Response to RT will be determined on follow-up at 7 and 12 weeks in both the arms and phone call interviews when necessary for completeness in patients with poor compliance to follow up.

  5. Quality of Life using EORTC QLQC30 questionnaires [ Time Frame: At start of radiotherapy, 12 week and at 3, 6, 9 & 12 months follow up. ]

    Quality of Life using EORTC QLQC 30 questionnaire (European Organisation for Research & Treatment of Cancer - Quality of Life Questionnaire of Cancer patients) will be evaluated at start of radiotherapy and at week 12, 3 month, 6 month, 9 month,12 months follow up.

    Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4.

    1 will be considered as better outcome & 4 will be considered as worst outcome.


  6. Quality of Life using EORTC QLQC-15 Pall questionnaires [ Time Frame: At start of radiotherapy, 12 week and at 3, 6, 9 & 12 months follow up. ]

    Quality of Life using EORTC QLQC-15 Pall (European Organisation for Research & Treatment of Cancer - Quality of Life Questionnaire in Palliative Cancer care patients) will be evaluated at start of radiotherapy and at week 12, 3 month, 6 month, 9 month,12 months follow up.

    Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4.

    1 will be considered as better outcome & 4 will be considered as worst outcome.


  7. Quality of Life using Cx-24 questionnaires [ Time Frame: At start of radiotherapy, 12 week and at 3, 6, 9 & 12 months follow up. ]

    Quality of Life using Cx-24 questionnaires (European Organisation for Research & Treatment of Cancer - Quality of Life Questionnaire of Cervical cancer patients) will be evaluated at start of radiotherapy and at week 12, 3 month, 6 month, 9 month,12 months follow up.

    Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4.

    1 will be considered as better outcome & 4 will be considered as worst outcome.


  8. Acute gastrointestinal and genitourinary toxicities [ Time Frame: Within 90 days of Radiotherapy ]
    Acute gastrointestinal and genitourinary toxicities using CTCAE ver4.0 grading will be measured within 90 days of Radiotherapy.

  9. Late gastrointestinal and genitourinary toxicities [ Time Frame: After 90 days of Radiotherapy ]
    Late gastrointestinal and genitourinary toxicities using CTCAE 4.0 grading will be measured after 90 days of Radiotherapy.

  10. Overall survival, defined as time from randomization until death due to any cause. [ Time Frame: 1 year ]
    Overall survival, defined as time from randomization until death due to any cause.

  11. Patterns of terminal event (Due to local relapse or Distant Metastasis) [ Time Frame: By telephonic interview of the relatives at 3, 6, 9 or 12 months, as applicable ]
    Events leading to death will be determined by telephonic interview of the relatives at 3, 6, 9 or 12 months, as applicable to find out the terminal cause of death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   This study is about cervical cancer.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Locally advanced cervical cancer (Stage IIIB-IVA) deemed unsuitable for full course radical pelvic radiotherapy or chemoradiation due to the following reasons:

    • Very large volume hard fixed disease infiltrating pelvic wall muscles and ligaments on clinical examination also classified clinically as "frozen pelvis" wherein curative intent treatment is not envisaged or feasible.
    • Fistulous communication between tumour growth and rectum and bladder >2x2 cm in size (as judged by cystoscopy for bladder infiltration or clinical or proctosigmoidoscopy examination for rectal/sigmoid infiltration) wherein radical intent treatment is not intended or feasible and patient is not a candidate for pelvic exenteration.
    • Deranged renal parameters as measured by Serum Creatinine >3 mg/dl wherein diversion nephrostomy is not planned by the multidisciplinary team due to anticipated poor clinical outcomes.Furthermore concurrence for palliative intent radiotherapy should be corroborated by 2 staff radiation oncologists.
  2. Moderate to Severe Pain on Numerical Rating Score (Score 4 or higher).
  3. Anticipated survival < 12 months.
  4. Patients with stage IVB with local disease extent as described in section 1 but systemic chemotherapy is not possible either due to deranged renal function or anticipated poor tolerance.

Exclusion Criteria:

  1. Patients with distant metastasis needing upfront systemic therapy.
  2. Presence of retroviral disease
  3. Non-compliant for follow up.
  4. Expected survival <3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03997110


Contacts
Layout table for location contacts
Contact: Supriya Chopra 02227405000 ext 5113 supriyasastri@gmail.com
Contact: TMH Gyn DMG TMC 02224177000 ext 6038 gwg.tmc@gmail.com

Locations
Layout table for location information
India
Tata Memorial Hospital
Mumbai, Maharastra, India, 400012
Principal Investigator: Supriya Sastri         
Sponsors and Collaborators
Tata Memorial Hospital
Tata Memorial Centre
Investigators
Layout table for investigator information
Principal Investigator: Supriya Sastri Tata Memorial Hospital
Layout table for additonal information
Responsible Party: Supriya Sastri (chopra), Professor, Tata Memorial Hospital
ClinicalTrials.gov Identifier: NCT03997110    
Other Study ID Numbers: TMH IRB 3157
First Posted: June 25, 2019    Key Record Dates
Last Update Posted: March 20, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Supriya Sastri (chopra), Tata Memorial Hospital:
Cervical Cancer
Palliative treatment
Radiation Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female